Literature DB >> 21532839

Metabolic imbalance and prostate cancer progression.

Anya J Burton, Kate M Tilling, Jeff M Holly, Freddie C Hamdy, Mari-Anne E Rowlands, Jenny L Donovan, Richard M Martin.   

Abstract

There is substantial evidence implicating environmental factors in the progression of prostate cancer. The metabolic consequences of a western lifestyle, such as obesity, insulin resistance and abnormal hormone production have been linked to prostate carcinogenesis through multiple overlapping pathways. Insulin resistance results in raised levels of the mitogens insulin and insulin-like growth factor-1, both of which may affect prostate cancer directly, or through their effect on other metabolic regulators. Obesity is associated with abnormal levels of adipocyte-derived peptides (adipokines), sex hormones and inflammatory cytokines. Adipokines have been shown to influence prostate cancer in both cell culture studies and observational, population level studies. Testosterone appears to have a complex relationship with prostate carcinogenesis, and it has been suggested that the lower levels associated with obesity may select for more aggressive androgen independent prostate cancer cells. Prostatic inflammation, caused by infection, urinary reflux or dietary toxins, frequently occurs prior to cancer development and may influence progression to advanced disease. High levels of ω-6 fatty acids in the diet may lead to the production of further inflammatory molecules that may influence prostate cancer. Increased fatty acid metabolism occurs within tumour cells, providing a potential target for prostate cancer therapies. Aberrations in amino acid metabolism have also been identified in prostate cancer tissue, particularly in metastatic cancer. This evidence indicates lifestyle interventions may be effective in reducing the incidence of clinical disease. However, much more research is needed before recommendations are made.

Entities:  

Keywords:  Prostate cancer; adipokines; diabetes; inflammation; insulin-like growth factors; metabolism; obesity

Year:  2010        PMID: 21532839      PMCID: PMC3076778     

Source DB:  PubMed          Journal:  Int J Mol Epidemiol Genet        ISSN: 1948-1756


  175 in total

1.  Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis.

Authors:  Shahrokh F Shariat; Dolores J Lamb; Michael W Kattan; Cuong Nguyen; JaHong Kim; Josie Beck; Thomas M Wheeler; Kevin M Slawin
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

Review 2.  The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer.

Authors:  Elizabeth A Platz; Edward Giovannucci
Journal:  J Steroid Biochem Mol Biol       Date:  2005-01-05       Impact factor: 4.292

Review 3.  The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity.

Authors:  Brent E Wisse
Journal:  J Am Soc Nephrol       Date:  2004-11       Impact factor: 10.121

4.  Leptin in relation to prostate cancer and benign prostatic hyperplasia.

Authors:  P Lagiou; L B Signorello; D Trichopoulos; A Tzonou; A Trichopoulou; C S Mantzoros
Journal:  Int J Cancer       Date:  1998-03-30       Impact factor: 7.396

5.  Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions.

Authors:  David J Degraff; Adam A Aguiar; Robert A Sikes
Journal:  Am J Transl Res       Date:  2009-01-20       Impact factor: 4.060

6.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.

Authors:  Arun Sreekumar; Laila M Poisson; Thekkelnaycke M Rajendiran; Amjad P Khan; Qi Cao; Jindan Yu; Bharathi Laxman; Rohit Mehra; Robert J Lonigro; Yong Li; Mukesh K Nyati; Aarif Ahsan; Shanker Kalyana-Sundaram; Bo Han; Xuhong Cao; Jaeman Byun; Gilbert S Omenn; Debashis Ghosh; Subramaniam Pennathur; Danny C Alexander; Alvin Berger; Jeffrey R Shuster; John T Wei; Sooryanarayana Varambally; Christopher Beecher; Arul M Chinnaiyan
Journal:  Nature       Date:  2009-02-12       Impact factor: 49.962

7.  Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy.

Authors:  Shahrokh F Shariat; Veronica A Anwuri; Dolores J Lamb; Nina V Shah; Thomas M Wheeler; Kevin M Slawin
Journal:  J Clin Oncol       Date:  2004-05-01       Impact factor: 44.544

Review 8.  Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence.

Authors:  Diana Barb; Catherine J Williams; Anke K Neuwirth; Christos S Mantzoros
Journal:  Am J Clin Nutr       Date:  2007-09       Impact factor: 7.045

9.  Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis.

Authors:  Ebba Bråkenhielm; Niina Veitonmäki; Renhai Cao; Shinji Kihara; Yuji Matsuzawa; Boris Zhivotovsky; Tohru Funahashi; Yihai Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

10.  Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer.

Authors:  Pablo Sáenz-López; Rafael Carretero; José Manuel Cózar; José Maria Romero; Julia Canton; José Ramón Vilchez; Miguel Tallada; Federico Garrido; Francisco Ruiz-Cabello
Journal:  BMC Cancer       Date:  2008-12-19       Impact factor: 4.430

View more
  4 in total

1.  Should visceral fat, strictly linked to hepatic steatosis, be depleted to improve survival?

Authors:  Carmine Finelli; Giovanni Tarantino
Journal:  Hepatol Int       Date:  2012-10-26       Impact factor: 6.047

2.  Preclinical Evaluation of 11C-Sarcosine as a Substrate of Proton-Coupled Amino Acid Transporters and First Human Application in Prostate Cancer.

Authors:  Morand Piert; Xia Shao; David Raffel; Mathew S Davenport; Jeffrey Montgomery; Lakshmi Priya Kunju; Brian G Hockley; Javed Siddiqui; Peter J H Scott; Arul M Chinnaiyan; Thekkelnaycke Rajendiran
Journal:  J Nucl Med       Date:  2017-03-16       Impact factor: 10.057

3.  Author'S reply.

Authors:  Simona Di Francesco; Raffaele L Tenaglia
Journal:  Cent European J Urol       Date:  2014

4.  Male hormone-interfering drugs and meningioma development.

Authors:  Laura Giraldi; Jørgen Vinsløv Hansen; Jan Wohlfahrt; Mads Melbye; Kåre Fugleholm; Tina Nørgaard Munch
Journal:  Neurooncol Adv       Date:  2019-11-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.